As IL-2 release and autocrine IL-2 receptor signaling seemed crucial in counteracting TGF-β repression, but CAR-T cell-released IL-2 negatively impacts the anti-tumor activity through sustaining survival and function of Treg cells, another elegant strategy to improve resistance to TGF-β is the engineering of a hybrid IL7/IL2 receptor to provide IL2 signaling upon IL7 binding. This evidence concerns the gene IL7 and neoplasm.